Target Hospitality(TH)

Search documents
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
Globenewswire· 2025-03-25 21:45
Core Viewpoint - Theratechnologies Inc. has received FDA approval for the new formulation of tesamorelin, named EGRIFTA WR™, which is set to replace the existing EGRIFTA SV formulation, offering improved convenience and patient experience [2][3][5]. Company Overview - Theratechnologies is a commercial-stage biopharmaceutical company focused on innovative therapies, with its stock listed on TSX and NASDAQ [10]. Product Details - EGRIFTA WR™ is the only FDA-approved medication for reducing excess abdominal fat in adults with HIV-related lipodystrophy [3]. - The new formulation requires less than half the administration volume compared to the previous EGRIFTA SV, which necessitated daily reconstitution [3]. - EGRIFTA WR™ is supplied in four single-patient-use vials, each containing 11.6 mg of tesamorelin, sufficient for seven doses, with a daily dose of 1.28 mg [4]. - The product can be stored at room temperature before and after reconstitution [4]. Clinical Significance - Central adiposity is a common complication for people with HIV, and the new formulation aims to address this issue effectively [5]. - The new formulation is expected to enhance patient compliance and experience in managing comorbidities associated with HIV [4][5]. Manufacturing and Patent Information - EGRIFTA WR™ will be manufactured at a new U.S.-based contract drug manufacturing organization (CDMO) [5]. - The formulation is patent protected in the U.S. until 2033 [5].
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Globenewswire· 2025-03-12 11:30
Core Insights - Ibalizumab shows long-term efficacy and safety in reducing HIV RNA to undetectable levels in heavily treatment-experienced patients with multidrug-resistant HIV [1][2][6] - The PROMISE-US study indicates that patients on ibalizumab-containing regimens achieve similar rates of undetectable viral loads compared to those on non-ibalizumab regimens, despite having more severe HIV disease at baseline [2][4] Study Details - The PROMISE-US study is a phase 4, multicenter, observational registry study designed to assess the efficacy and durability of ibalizumab in combination with other antiretroviral therapies [3][6] - The interim analysis included 112 participants, with 70 in the non-ibalizumab cohort and 42 in the ibalizumab cohort, showing baseline viremia rates of 39% and 57% respectively [4] Treatment Outcomes - Among participants with baseline viremia, 50% of those in the non-ibalizumab cohort and 47% in the ibalizumab cohort achieved undetectable viral loads after six months [5] - At 12 months, 53% of the non-ibalizumab cohort and 42% of the ibalizumab cohort had undetectable viral loads [5] Safety Profile - Ibalizumab was well-tolerated, with no infusion reactions reported and no treatment discontinuations due to adverse events in the ibalizumab cohort [5]
Target Hospitality Announces Fourth Quarter and Full Year 2024 Earnings Release and Conference Call Schedule
Prnewswire· 2025-03-12 10:45
Core Points - Target Hospitality Corp. will release its fourth quarter and full year 2024 financial results on March 26, 2025, before the market opens [1] - A conference call to discuss the results is scheduled for the same day at 9:00 AM Eastern Time [1][3] - The conference call will be accessible via live webcast on the company's website [2] Company Overview - Target Hospitality is one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services [5] - The company builds, owns, and operates a customized network of communities, offering a full suite of services including food service management, concierge, laundry, logistics, security, and recreational facilities [5]
Arrow Bidco, LLC Announces Redemption of Senior Secured Notes Due 2025
Prnewswire· 2025-03-10 17:45
Core Viewpoint - Target Hospitality Corp. announced the redemption of all $181.4 million of its 10.75% senior secured notes due 2025, scheduled for March 25, 2025, at a redemption price of 101.000% of the principal amount plus accrued interest [1][2]. Company Overview - Target Hospitality is one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, offering a range of solutions including food service management, concierge, laundry, logistics, security, and recreational facilities services [5].
Target Hospitality Announces 5-year Contract Award Reactivating South Texas Assets
Prnewswire· 2025-03-06 11:45
Core Viewpoint - Target Hospitality Corp has entered into a five-year lease and services agreement with CoreCivic to reactivate operations at the Dilley Facility in Texas, which will support up to 2,400 individuals and is expected to generate over $246 million in revenue over its term [1][4][3] Company Overview - Target Hospitality is one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, offering a range of solutions including food service management, concierge, laundry, logistics, security, and recreational facilities [8] Contract Details - The Dilley Contract will maintain a similar economic structure to the previous agreement with CoreCivic, including fixed minimum revenue regardless of occupancy, with an anticipated revenue of approximately $30 million in 2025 [4][6] - The Dilley Facility previously operated from September 2014 to August 2024 as the South Texas Family Residential Center, and its reactivation will require no capital investment due to the consistency of the community layout [2][3] Strategic Importance - The reactivation of the Dilley Facility highlights Target's flexible operating model and unique capabilities, positioning the company to respond effectively to customer demand and pursue additional growth opportunities aligned with U.S. government immigration policies [5][6] - The Dilley Contract is supported by an amended intergovernmental services agreement with U.S. Immigration and Customs Enforcement, subject to annual appropriations and potential cancellation with 60 days' notice [7]
Earnings Preview: Target Hospitality (TH) Q4 Earnings Expected to Decline
ZACKS· 2025-03-05 16:00
Company Overview - Target Hospitality (TH) is expected to report a year-over-year decline in earnings, with a projected EPS of $0.07, reflecting a decrease of 75.9% compared to the previous year [3] - Revenues are anticipated to be $80.1 million, down 36.5% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 80.77% over the last 30 days, indicating a significant reassessment by analysts [4] - The Most Accurate Estimate for Target Hospitality is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -25%, suggesting a bearish outlook from analysts [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of an earnings beat or miss, with a strong predictor being a positive Earnings ESP combined with a favorable Zacks Rank [8][9] - Target Hospitality currently holds a Zacks Rank of 3 (Hold), making it challenging to predict an earnings beat [11] Historical Performance - In the last reported quarter, Target Hospitality exceeded the consensus EPS estimate of $0.12 by delivering earnings of $0.20, resulting in a surprise of +66.67% [12] - Over the past four quarters, the company has successfully beaten consensus EPS estimates on all occasions [13] Industry Comparison - Vail Resorts (MTN), a peer in the Zacks Leisure and Recreation Services industry, is expected to report an EPS of $6.29, reflecting a year-over-year increase of 9.2% [17] - Vail Resorts' revenues are projected to be $1.14 billion, up 5.6% from the previous year, with an Earnings ESP of 1.64% indicating a likelihood of beating the consensus EPS estimate [18]
Target Hospitality (TH) Loses -41.46% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ZACKS· 2025-02-26 15:36
Core Viewpoint - Target Hospitality (TH) has experienced significant selling pressure, resulting in a 41.5% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. - TH's current RSI reading is 21.07, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5]. Group 2: Fundamental Indicators - There is a consensus among sell-side analysts that earnings estimates for TH have increased by 1.9% over the last 30 days, which often correlates with price appreciation [6]. - TH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, further supporting the potential for a turnaround [7].
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
Globenewswire· 2025-02-26 12:30
Core Insights - Theratechnologies Inc. reported strong financial results for Q4 and FY2024, with a notable increase in revenue and positive Adjusted EBITDA, indicating a solid performance and growth potential in its HIV portfolio and new product lines [3][6][30]. Financial Performance - Q4 2024 revenue reached $25 million, a 6.6% increase from Q4 2023, while annual revenue for FY2024 was $85.9 million, up 5.0% year-over-year [2][30]. - EGRIFTA SV net sales for Q4 2024 were $17.7 million, a 4.2% increase from the previous year, and full-year sales were $60.1 million, reflecting a 12% growth [2][31]. - Trogarzo net sales in Q4 2024 were $7.3 million, a 12.8% increase, but full-year sales decreased by 8.3% to $25.7 million due to competitive pressures [2][32][33]. - Adjusted EBITDA for Q4 2024 was $7.8 million, a 56% increase from Q4 2023, and for FY2024, it reached $20.2 million compared to a negative $2.9 million in FY2023 [3][42]. Operational Highlights - The company secured $75 million in new credit facilities, enhancing its financial flexibility and supporting its growth strategy [3][10]. - A temporary supply disruption for EGRIFTA SV was resolved, allowing the company to resume distribution and meet market demand [5][48]. - The FDA has set a PDUFA action date of March 25, 2025, for the updated F8 formulation of tesamorelin, which could replace the current formulation [9]. Strategic Developments - The company in-licensed two new investigational drugs, olezarsen and donidalorsen, to drive long-term growth in Canada [11][60]. - Theratechnologies is actively seeking a partner for its oncology program to advance its novel peptide drug conjugates [4][12]. Cost Management - R&D expenses for FY2024 decreased significantly to $17 million from $30.4 million in FY2023, primarily due to reduced spending on various programs [35]. - Selling expenses for FY2024 were $25.4 million, down from $26.8 million in FY2023, reflecting tighter expense control [38]. Financial Position - As of November 30, 2024, the company had cash and cash equivalents totaling $19.8 million, down from $40.4 million a year earlier, indicating a need for careful cash flow management [53]. - The company reported a net loss of $8.3 million for FY2024, an improvement from a loss of $24 million in FY2023 [44].
Target Hospitality Provides Update on Pecos Children's Center Contract
Prnewswire· 2025-02-24 11:45
Core Viewpoint - The U.S. government intends to terminate the Pecos Children's Center services agreement with Target Hospitality's nonprofit partner, effective around February 21, 2025, impacting the company's operations and financial outlook [1][2][5]. Group 1: Contract Termination - The Pecos Children's Center services agreement (PCC Contract) provided facility and hospitality solutions for up to 6,000 individuals, and the nonprofit partner has notified Target of its intention to terminate this contract [2]. - The termination of the PCC Contract allows the company to retain ownership of its modular assets, which can still be utilized for other customer demands and growth opportunities [3]. Group 2: Growth Opportunities - Target Hospitality is actively re-marketing its modular assets and exploring a pipeline of growth opportunities, particularly in relation to U.S. government immigration policies [4]. - The company plans to provide operational and financial updates in light of the contract termination, indicating a shift in its financial outlook for 2025 [5]. Group 3: Company Overview - Target Hospitality is one of North America's largest providers of vertically integrated modular accommodations and hospitality services, offering a range of value-added solutions including food service management and logistics [6].
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Globenewswire· 2025-02-14 12:30
MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2024 ended November 30 on Wednesday, February 26, 2025, at 8:30 a.m. ET. The call will be hosted b ...